Last reviewed · How we verify

NCT03889483

Neurophysiological Measurements Using the NeuroCatch™ Platform in Pediatric Concussion

Status unknown NA Last updated 13 January 2021
What this trial tests

NA trial testing NeuroCatch™ Platform in Children, Only in 105 participants. Status unknown.

Timeline
30 November 2018
Primary endpoint
30 September 2021
30 December 2021

Quick facts

Lead sponsorDr. Michael Esser
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment105
Start date30 November 2018
Primary completion30 September 2021
Estimated completion30 December 2021
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Dr. Michael Esser

Who can join

Adults 8 to 18, any sex, with Children, Only or Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

EEG signals have been collected and studied since the early 1990's as a way of assessing brain function at a gross level. As early as the 1930's a derivative of the raw EEG signal - event-related potentials (ERPs) - have been computed. The current research is primarily focused on three ERP components: the N100, P300 and N400. Each of the three ERPs have been studied in the academic laboratory for multiple decades. Through this research, a strong understanding has been developed regarding what can affect these components (e.g. task set, emotional state, etc.). However, these signals within various pediatric populations (e.g., those with persistent mTBI symptoms or multiple concussions) are not well characterized. Being able to safely and effectively employ the NeuroCatch™ Platform in a post-concussive pediatric cohort could provide researchers with the potential to elucidate the persistence of objective measures of impairment, patterns of recovery, and chronicity of problems due to mTBI in children. Secondly, understanding the degree to which these neurophysiological components fluctuate over time is crucial to the understanding of brain functioning. However, for this type of technology to be useful in quantifying brain health in this population,the degree to which a post-concussive pediatric brain naturally fluctuates in its processing capability must be quantified. NeuroCatch™ Platform has the ability to measure changes in several domains of brain function. These cognitive processes are foundational blocks for some of the highest cognitive processes: information integration and executive functioning.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of NeuroCatch™ Platform

Trials testing the same drug.

Other recruiting trials for Children, Only

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03889483.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing